IL312466A - PI3K-alpha inhibitors and methods for their preparation and use - Google Patents
PI3K-alpha inhibitors and methods for their preparation and useInfo
- Publication number
- IL312466A IL312466A IL312466A IL31246624A IL312466A IL 312466 A IL312466 A IL 312466A IL 312466 A IL312466 A IL 312466A IL 31246624 A IL31246624 A IL 31246624A IL 312466 A IL312466 A IL 312466A
- Authority
- IL
- Israel
- Prior art keywords
- pi3k
- making
- methods
- same
- alpha inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
- C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/33—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of six-membered aromatic rings being part of condensed ring systems
- C07C309/34—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of six-membered aromatic rings being part of condensed ring systems formed by two rings
- C07C309/35—Naphthalene sulfonic acids
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163263474P | 2021-11-03 | 2021-11-03 | |
| CN2021128533 | 2021-11-03 | ||
| PCT/US2022/079221 WO2023081757A1 (en) | 2021-11-03 | 2022-11-03 | Pi3k-alpha inhibitors and methods of making and using the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL312466A true IL312466A (en) | 2024-06-01 |
Family
ID=86242193
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL312466A IL312466A (en) | 2021-11-03 | 2022-11-03 | PI3K-alpha inhibitors and methods for their preparation and use |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20260125374A1 (enExample) |
| EP (1) | EP4426314A4 (enExample) |
| JP (1) | JP2024540303A (enExample) |
| KR (1) | KR20240112283A (enExample) |
| CN (1) | CN118401245A (enExample) |
| AU (1) | AU2022381187A1 (enExample) |
| CA (1) | CA3236861A1 (enExample) |
| CL (1) | CL2024001364A1 (enExample) |
| IL (1) | IL312466A (enExample) |
| MX (1) | MX2024005429A (enExample) |
| PE (1) | PE20250676A1 (enExample) |
| TW (1) | TW202334136A (enExample) |
| WO (1) | WO2023081757A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021263914B2 (en) | 2020-04-29 | 2026-07-23 | D.E. Shaw Research, Llc | PI3K-α inhibitors and methods of use thereof |
| WO2024055992A1 (zh) * | 2022-09-14 | 2024-03-21 | 南京再明医药有限公司 | 三环化合物及其应用 |
| JP2025538147A (ja) | 2022-11-02 | 2025-11-26 | ペトラ・ファーマ・コーポレイション | 疾患の治療のためのホスホイノシチド３－キナーゼ（ｐｉ３ｋ）のアロステリックポケット及びオルソステリックポケットの標的化 |
| WO2024233256A1 (en) | 2023-05-05 | 2024-11-14 | Eli Lilly And Company | Imlunestrant or salts thereof for use in treating and preventing central nervous system (cns) metastases in subjects having er+ breast cancer |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010007100A1 (en) * | 2008-07-15 | 2010-01-21 | Cellzome Ltd | 7-substituted amino triazoles as pi3k inhibitors |
| JP6472803B2 (ja) * | 2013-09-05 | 2019-02-20 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | トリアゾロピリジン化合物、その組成物及び使用方法 |
| WO2017000277A1 (en) * | 2015-07-01 | 2017-01-05 | Merck Sharp & Dohme Corp. | Substituted triazolo bicycliccompounds as pde2 inhibitors |
| EP3931188B1 (en) * | 2019-02-26 | 2023-08-30 | Boehringer Ingelheim International GmbH | New isoindolinone substituted indoles and derivatives as ras inhibitors |
| AU2021263914B2 (en) * | 2020-04-29 | 2026-07-23 | D.E. Shaw Research, Llc | PI3K-α inhibitors and methods of use thereof |
-
2022
- 2022-11-02 TW TW111141786A patent/TW202334136A/zh unknown
- 2022-11-03 PE PE2024001004A patent/PE20250676A1/es unknown
- 2022-11-03 WO PCT/US2022/079221 patent/WO2023081757A1/en not_active Ceased
- 2022-11-03 KR KR1020247018494A patent/KR20240112283A/ko active Pending
- 2022-11-03 AU AU2022381187A patent/AU2022381187A1/en active Pending
- 2022-11-03 CN CN202280082873.4A patent/CN118401245A/zh active Pending
- 2022-11-03 JP JP2024526614A patent/JP2024540303A/ja active Pending
- 2022-11-03 IL IL312466A patent/IL312466A/en unknown
- 2022-11-03 EP EP22891040.2A patent/EP4426314A4/en active Pending
- 2022-11-03 CA CA3236861A patent/CA3236861A1/en active Pending
- 2022-11-03 US US18/706,511 patent/US20260125374A1/en active Pending
- 2022-11-03 MX MX2024005429A patent/MX2024005429A/es unknown
-
2024
- 2024-05-03 CL CL2024001364A patent/CL2024001364A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CL2024001364A1 (es) | 2024-10-25 |
| KR20240112283A (ko) | 2024-07-18 |
| EP4426314A1 (en) | 2024-09-11 |
| MX2024005429A (es) | 2024-05-21 |
| CN118401245A (zh) | 2024-07-26 |
| JP2024540303A (ja) | 2024-10-31 |
| EP4426314A4 (en) | 2025-10-01 |
| US20260125374A1 (en) | 2026-05-07 |
| PE20250676A1 (es) | 2025-03-04 |
| CA3236861A1 (en) | 2023-05-11 |
| AU2022381187A1 (en) | 2024-05-16 |
| TW202334136A (zh) | 2023-09-01 |
| WO2023081757A1 (en) | 2023-05-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES3065954T3 (en) | Fgfr inhibitors and methods of use thereof | |
| IL299704A (en) | Tetrahydropyrazolo-pyrazinyl-dihydroimidazolone or tetrahydropyrazolo-pyridinyl-dihydroimidazolone compounds and methods of using them | |
| IL297625B2 (en) | PI3K-alpha inhibitors and methods of using them | |
| PT3911648T (pt) | 6¿-[[(1s,3s)-3-[[5-(difluorometoxi)-2-pirimidinil]amino]ciclopentil]amino][1(2h),3¿-bipiridina]-2-ona como inibidor de pcsk9 e seus métodos de utilização | |
| IL291285B1 (en) | Inhibitors of shp2 phosphatases and methods for their preparation and use | |
| SG11202105769XA (en) | Inhibitors of apol1 and methods of using same | |
| IL287973A (en) | acss2 inhibitors and methods of their use | |
| IL304728A (en) | cdk2 inhibitors and methods of using them | |
| IL279475A (en) | Actonucleotidase inhibitors and methods of using them | |
| IL312348A (en) | HIF-2ALPHA inhibitors and methods of using it | |
| AU2021383928A9 (en) | Fgfr inhibitors and methods of making and using the same | |
| EP4247384A4 (en) | FGFR INHIBITORS AND METHODS FOR THE PRODUCTION AND USE THEREOF | |
| EP3986894A4 (en) | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | |
| IL305834A (en) | Phenalkylamines and methods for their preparation and use | |
| IL287293A (en) | RNA editing inhibitors and methods of use | |
| IL264854A (en) | Spt5 inhibitors and methods of use thereof | |
| IL289127A (en) | ppm1a inhibitors and methods of using them | |
| EP3959197A4 (en) | PAPD5 INHIBITORS AND METHODS OF USE THEREOF | |
| IL321255A (en) | ADAR1 inhibitors and methods of using them | |
| GB202119051D0 (en) | Wingsail and method of use | |
| IL286149A (en) | Caspase inhibitors and methods of using them | |
| IL285108A (en) | Arginase inhibitors and methods of using them | |
| HK40114456A (en) | Pi3k-alpha inhibitors and methods of making and using the same | |
| HK40069053A (en) | Kcnt1 inhibitors and methods of use | |
| HK40064703A (en) | Ectonucleotidase inhibitors and methods of use thereof |